Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

[1]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[2]  D. Cameron,et al.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. , 2014, The Lancet. Oncology.

[3]  R. Peto,et al.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials , 2014, The Lancet.

[4]  G. Hortobagyi,et al.  Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy , 2013 .

[5]  K. Gelmon,et al.  Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13) , 2013 .

[6]  N. Wolmark,et al.  Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) , 2013 .

[7]  A. Schneeweiss,et al.  German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Schneeweiss,et al.  Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies. , 2013 .

[9]  J. Forbes,et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[12]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[13]  M. Gnant.  Zoledronic acid in breast cancer: latest findings and interpretations , 2011, Therapeutic advances in medical oncology.

[14]  G. Hortobagyi,et al.  Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Hortobagyi,et al.  Future directions of bone-targeted therapy for metastatic breast cancer , 2010, Nature Reviews Clinical Oncology.

[16]  D. Mavroudis,et al.  Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Spiegelhalter,et al.  Monitoring of large randomised clinical trials: a new approach with Bayesian methods , 2001, The Lancet.

[20]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.